Sarcura provides an autonomous, miniaturized device platform that automates the entire cell therapy manufacturing workflow within a compact, closed cartridge. Leveraging semiconductor chip technology, microfluidics, and machine‑learning‑driven control intelligence, the system delivers precise, cell‑level processing, real‑time quality assurance, and modular configurability for various cell therapy modalities, dramatically lowering costs and increasing production capacity for biopharma manufacturers and CDMOs.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
5OXSFounders
Product
Problem
Current cell therapy manufacturing is labor-intensive, manually operated, and requires large, expensive facilities, leading to high production costs, limited scalability, and variability that restricts patient access to these treatments.
Solution
Sarcura has created an autonomous, miniaturized device platform that automates the entire cell therapy production workflow within a compact, closed cartridge. The system leverages semiconductor chip technology and microfluidic channels to handle cells at the cellular level, while integrated control intelligence performs real-time process monitoring and quality control without human intervention. Its modular architecture allows customized process configurations for different cell types, enabling rapid adaptation to new therapies. By eliminating manual steps and reducing the physical footprint, the platform dramatically lowers operating costs, increases manufacturing capacity, and improves batch-to-batch consistency, making cell therapies more affordable and widely available.
Target Audience
Primary customers are biopharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs) developing autologous or allogeneic cell therapies, as well as academic and hospital labs seeking scalable, cost‑effective production solutions.
Features
- On‑chip microfluidic processing combined with semiconductor photonic/electronic structures for precise cell manipulation in a single‑use cartridge
- Machine‑learning‑driven control intelligence that autonomously executes processing steps and performs real‑time quality assurance for each batch
- Fully closed, sterile system that removes manual handling, reducing contamination risk and documentation overhead
- Modular functional blocks that can be reconfigured to support various cell therapy modalities (e.g., CAR‑T, NK‑cell, stem‑cell products)
- Scalable automation that enables high‑throughput production while maintaining cell‑level certainty and reproducibility
- Integrated data acquisition and analytics platform providing traceable process metrics and batch records